Home LiteratureArticle Details
PMID: 16601876 Published · ppublish English Case Reports Journal Article

Manifestations of Fabry disease in placental tissue.

Journal of inherited metabolic disease ·Vol. 29 ·No. 1 ·2006-02-00 ·Pages 106-11

Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by deficiency of the lysosomal enzyme alpha-galactosidase A. Manifestations of the disease in placental tissue have been reported only twice. We report for the first time on the biochemical, histological and genetic features of two cases: placenta A derived from a mother heterozygous for Fabry disease who gave birth to a hemizygous son, and placenta B obtained from a healthy mother who carried a heterozygous daughter. Biopsies of placentae A, B and of four healthy controls were taken directly after birth. Assessment of alpha-galactosidase A (alpha-Gal) activity was performed both in fetal leukocytes (derived from umbilical cord blood) and in the biopsy specimens. The tissue was further examined by electron microscopy, immunohistochemistry and biochemical analysis for the presence of storage material (ceramide trihexoside (CTH)). In placenta A, characteristic zebra bodies reflecting accumulated storage material were seen in all biopsies evaluated. CTH values were markedly elevated as compared to the controls and alpha-Gal activity in both fetal leukocytes and placental tissue was very low. Placenta B showed no storage material at all. CTH values were within the control range. alpha-Gal activity ranged from intermediate to near normal; enzyme activity in fetal leukocytes was significantly decreased. As placental tissue is mainly derived from fetal cells, we may conclude that, in a boy suffering from Fabry disease, extensive storage of CTH is already present at birth. As complications develop only around the age of 10 years, it may be not the CTH itself but secondary processes that cause cellular and organ damage.

MeSH Terms
Adult Fabry Disease/diagnosis,metabolism Female Heterozygote Humans Immunohistochemistry Infant, Newborn Lipids/chemistry Male Microscopy, Electron Placenta/metabolism,ultrastructure alpha-Galactosidase/metabolism
Chemicals
Lipids alpha-Galactosidase
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Vedder A C
Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands. [email protected]
Strijland A
vd Bergh Weerman M A
Florquin S
Aerts J M F G
Hollak C E M
References (15)
15 references, click to expand
  1. Fabry's disease: alpha-galactosidase deficiency.
    Science. 1970 Feb 27;167(3922):1268-9 PMID: 5411915
  2. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.
    Clin Chim Acta. 1981 May 5;112(2):247-51 PMID: 6263521
  3. Demonstration of Fabry's disease deposits in placenta.
    Am J Obstet Gynecol. 1990 Feb;162(2):464-5 PMID: 2155532
  4. LYONISATION OF THE X CHROMOSOME.
    Lancet. 1963 Nov 23;2(7317):1120-1 PMID: 14063435
  5. Measurement of protein using bicinchoninic acid.
    Anal Biochem. 1985 Oct;150(1):76-85 PMID: 3843705
  6. Corneal findings in a foetus with Fabry's disease.
    Acta Ophthalmol (Copenh). 1984 Dec;62(6):923-31 PMID: 6098121
  7. Prevalence of lysosomal storage disorders.
    JAMA. 1999 Jan 20;281(3):249-54 PMID: 9918480
  8. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.
    J Med Genet. 1996 Aug;33(8):682-8 PMID: 8863162
  9. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.
    Medicine (Baltimore). 2002 Mar;81(2):122-38 PMID: 11889412
  10. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    N Engl J Med. 2001 Jul 5;345(1):9-16 PMID: 11439963
  11. A rapid method of total lipid extraction and purification.
    Can J Biochem Physiol. 1959 Aug;37(8):911-7 PMID: 13671378
  12. [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I].
    Cesk Patol. 1998 Jan;34(1):7-12 PMID: 9560877
  13. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.
    N Engl J Med. 1967 May 25;276(21):1163-7 PMID: 6023233
  14. The frequency of lysosomal storage diseases in The Netherlands.
    Hum Genet. 1999 Jul-Aug;105(1-2):151-6 PMID: 10480370
  15. Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
    JAMA. 2001 Jun 6;285(21):2743-9 PMID: 11386930
Article Info
Journal
Journal of inherited metabolic disease
Abbr.
J Inherit Metab Dis
ISSN
0141-8955
Published
2006-02-00
Pages
106-11
Language
English
Region
United States
NLM ID
7910918
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]